AbbVie Stock
AbbVie Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Robert A. Michael
- Employees
- 57,000
- Market cap
- $504.4 B
- IPO
- 02/01/2013
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Headquartered in North Chicago, USA, the company was founded in 2012 and employs approximately 57,000 people. AbbVie is listed on the NYSE. Its extensive therapeutic…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
AbbVie stock: price history
1D
+0.7%
1W
+3.2%
1M
+8.7%
6M
+37.0%
YTD
+24.9%
1Y
+25.8%
2Y
+49.9%
5Y
+161.1%
10Y
+374.4%
Next earnings date
Next earnings date
30/10/2026 (in 13 days)
Volatility around earnings
~17% stronger price swings than usual
AbbVie stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
AbbVie Inc. is a globally operating biopharmaceutical company engaged in the discovery, development, and commercialization of highly specialized pharmaceuticals. Its portfolio spans various therapeutic areas such as immunology (for example, Humira, Skyrizi), oncology, virology, as well as gastroenterology and neurology. A substantial part of the business model is based on the treatment of chronic diseases, which generates stable revenue streams. Revenue activities are geographically highly concentrated in the United States (over 95 percent). The company also engages in research collaborations with partners such as Dragonfly Therapeutics, Inc.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about AbbVie
Analyst assessment of AbbVie
PRICE TARGET LOW
US$235.00
CONSENSUS
US$292.21
MEDIAN
US$300.00
PRICE TARGET HIGH
US$320.00
0
STRONG BUY
32
BUY
11
HOLD
1
SELL
0
STRONG SELL
44
TOTAL · Buy
As of: 13/10/2026
AbbVie stock metrics
P/E
80.41
P/B
-85.17
EV/EBITDA
26.84
RETURN ON EQUITY
-60.9%
NET MARGIN
21.3%
DEBT/EQUITY
-11.93
DIVIDEND YIELD
2.4%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
1,763,989,487
AVG. DAILY VOLUME (30D)
4,812,657
Insider transactions (SEC)
Donoghoe Nicholas
Donoghoe Nicholas
FALK THOMAS J
WADDELL FREDERICK H
FREYMAN THOMAS C
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.7%
Forums (Reddit)
Institutional holders
Dividends
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about AbbVie stock
What does AbbVie do?
AbbVie Inc. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Robert A. Michael, the company employs around 57,000 people.
The IPO was on 02/01/2013; the stock trades on NYSE under the ticker ABBV.
What do analysts say about AbbVie stock?
44 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$292.21, ranging from US$235.00 to US$320.00, with a median of US$300.00.
This is an external assessment, not a statement by Market Jury.
When does AbbVie report next?
The next earnings date is 30/10/2026.
Around past earnings, price swings were roughly 17% stronger than usual.
Does AbbVie pay a dividend?
Yes. The last dividend was US$1.73 per share, ex-date 15/10/2026, paid on 16/11/2026.
The dividend yield is 2.4% (as of 30/06/2026).
Which stocks are comparable to AbbVie?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, Merck &, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb Company and Biogen.
How can I get AbbVie stock analyzed?
Clicking "Analyze stock" lets five strategies assess AbbVie against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.